Breaking Finance News

AcelRx Pharmaceuticals Inc (NDAQ:ACRX) has been downgraded from Buy to Hold in a statement by Jefferies & Co earlier today.

Jefferies & Co has downgraded AcelRx Pharmaceuticals Inc (NDAQ:ACRX) from Buy to Hold in a statement released on Friday October 13, 2017.

Previously on 7/14/2017, Jefferies & Co released a statement about AcelRx Pharmaceuticals Inc (NDAQ:ACRX) increased the target price from $0.00 to $7.00. At the time, this indicated a possible upside of 1.89%.

Just yesterday AcelRx Pharmaceuticals Inc (NDAQ:ACRX) traded -59.81% lower at $2.15. The company’s 50-day moving average is $3.80 and its 200-day moving average is $2.97. The last closing price is down -27.73% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same time. 24,274,300 shares of AcelRx Pharmaceuticals Inc traded, up from an avg. volume of 2,214,920

Performance Chart

AcelRx Pharmaceuticals Inc (NDAQ:ACRX)

With a total market value of $0, AcelRx Pharmaceuticals Inc has with a one year low of $1.95 and a one year high of $5.75 .

A total of 4 firms have issued a research note on the company. 1 broker rating the company a strong buy, three equity analysts rating the company a buy, 2 firms rating the stock a hold, 0 firms rating the company a underperform, and finally zero analysts rating the company a sell with a one year target of $7.63.

Brief Synopsis On AcelRx Pharmaceuticals Inc (NDAQ:ACRX)

AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.